The alarming rate of obesity and weight gain in industrialized nations is one of the most concerning health issues plaguing developed countries today. Scientists might have just come much closer to finally ending this epidemic by preventing mice from gaining weight even with a steady diet of high-fat food. Could these findings lead to effortless weight loss?
Published on eLife, the study described how scientists from Washington University School of Medicine basically activated certain pathways in fat cells, which essentially allowed the mice to go on a high-fat diet without becoming obese. This could lead to some huge leaps in treating all the other diseases that are associated with weight gain, including type-2 diabetes.
“Here by inducing expression of constitutively active Smoothened (SmoM2) or Gli2 (ΔNGli2) in the adipocyte lineage of postnatal mice, we show that targeted activation of Hh signaling suppresses high-fat-diet-induced obesity and improves whole-body glucose tolerance and insulin sensitivity,” the study reads.
As senior investigator Fanxin Long, Ph.D. put it, these findings could lead to new ways to treat the growing obesity epidemic afflicting populations even in developing countries. It also makes preventing weight gain easier because it targets the root cause of the issue.
"This could lead us to a new therapeutic target for treating obesity," Long said. "What's particularly important is that the animals in our study ate a high-fat diet but didn't gain weight, and in people, too much fat in the diet is a common cause of obesity."
On that note, translating the results of this study to apply to humans might not be that easy, MedicalXpress reports. The test subjects and people don’t exactly have the same metabolism and the methods used to activate the pathways in fat cells to stop them from growing might cause unknown side-effects. It might even cause cancer if the application is not done properly.


Obamacare Premiums Set to Double in 2026 as Subsidy Expiration Looms Amid U.S. Shutdown
FDA Adds Fatal Risk Warning to J&J and Legend Biotech’s Carvykti Cancer Therapy
Senate Sets December 8 Vote on Trump’s NASA Nominee Jared Isaacman
U.S. Experts to Reassess Newborn Hepatitis B Vaccination Guidelines Amid Growing Debate
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment
U.S. Backs Bayer in Supreme Court Battle Over Roundup Cancer Lawsuits
Lost in space: MethaneSat failed just as NZ was to take over mission control – here’s what we need to know now
Novo Nordisk and Eli Lilly Lower Prices for Weight-Loss Drugs Amid U.S. Agreement
Major Drugmakers Slash U.S. Prices and Sell Directly to Patients Amid Trump’s Push for Affordable Medicines
Neuralink Expands Brain Implant Trials with 12 Global Patients
Eli Lilly Becomes First Pharma Giant to Hit $1 Trillion Amid Soaring Weight-Loss Drug Demand
Pfizer Boosts Bid for Metsera Amid Intensifying Rivalry with Novo Nordisk in Obesity Drug Market 



